Acute Repetitive Seizures Market Analysis, Sector / Industry Report & Analysis, 2018-2025 (Includes Business Impact of COVID-19)

  • TBI940438
  • August 01, 2019
  • Global
  • 132 pages
  • HCCResearch
                                              Abstract, Snapshot, Market Analysis & Market Definition: Global Acute Repetitive Seizures Market

The global acute repetitive seizures market size was estimated at USD 140.5 million in 2017 and is expected to register a CAGR of 47.8% over the forecast period. High unmet clinical needs for patients, as well as caregivers, and availability of advanced product pipeline are some of the major factors expected to propel market growth. Drug therapy is effective for most of the patients suffering from cluster seizures. However, there are a significant number of treatment challenges and unmet medical needs including drug induced seizures, adverse reactions, and lack of antiepileptogenic agents that can prevent development of seizures and its comorbidities.
In an attempt to curb healthcare expenditure, governments across the globe are making continuous efforts to reduce hospital stays and on-site patient treatment costs through outpatient care models, such as clinic and home healthcare. Emerging economies like India and China are increasingly implementing these healthcare reforms. This factor is expected to propel the growth of acute repetitive seizures market.
The treatment gap is a useful measure to compare access to quality care for patients suffering from seizures. The treatment gap for low- and middle-income countries, such as India, South Africa, and Brazil, is around 80%, while it is around 60% in developed countries, such as U.S. and U.K.
Among the many routes of medicine administration, patients prefer intranasal route over other types, such as buccal, rectal, and intramuscular route. Parenteral medications have proven to be the optimal option for outpatient treatment. However, in some countries, such as Netherlands, caregivers are not qualified for administrating parenteral medications.

Market Segmentation, Outlook & Viewpoint: Global Acute Repetitive Seizures Market

Product Market Segmentation & Outlook (Revenue, USD Million, 2013 - 2025)




Diastat Rectal Gel


Key Players, Recent Developments & Regional Insights: Global Acute Repetitive Seizures Market

Based on product, the market is categorized into USL-261, NRL-1, AZ-002, Diastat Rectal Gel {DRG}, and others. Diastat Rectal Gel led the product segment in 2017 owing to its efficiency and lack of FDA-approved drugs in the market. It is the only FDA-approved drug and the generic versions of it were introduced in 2010.
NRL-1 is expected to be the fastest-growing segment over the forecast period. It is an investigational drug developed by Neurelis to be used for children, adolescents, and adults. The company filed NDA with the FDA in September 2018. USL-261 is expected to show lucrative growth over the forecast years and is specifically designed for intranasal administration for outpatient use.

Regional Insights
U.S. held a share of 17.0% in 2017 in the global market. According to the data published by CDC, around 4.3 million adults and 750,000 children in U.S. had epilepsy in 2014. Also, the total direct and indirect cost of epilepsy in this region is estimated to be around USD 15.5 billion annually. Thus, presence of a large target population base for epilepsy drug in this region will spur the market growth.
Germany is expected to witness robust growth over the forecast period owing to technological advancements in scientific, clinical, and medical fields. Increasing demand for antiepileptic drugs due to rising disease prevalence in the region fosters the market growth. Government initiatives, in an attempt to improve the quality of life and awareness regarding the disease, coupled with promotion of better healthcare facilities are the major drivers boosting market growth in this region.
The Asia Pacific market is also likely to witness rapid development on account of increasing healthcare expenditure in developing countries, such as India and China. A huge gap was observed in the treatment for acute repetitive seizures in this region. Hence, the demand for the antiseizure drugs in these developing countries encourages a shift in market potential from the already saturated European and North American regions to such economies.
Acute Repetitive Seizures Market Share Insights
UCB S.A. and Neurelis, Inc. are likely to hold the major share of the global market due to the commercialization of USL-261 and VALTOCO. As both the drugs (USL-261 and VALTOCO) are granted orphan drug designation, the prices will be usually high. In addition, as per our studies, the preferred route of administration is nasal, which in turn will result into higher adoption of these two drugs.

Key Insights Covered: Global Acute Repetitive Seizures Market
1.  North America, Europe, Asia Pacific, Middle East & Africa, Latin America market size (sales, revenue and growth rate) of Acute Repetitive Seizures industry.
2. Global major manufacturers' operating situation (sales, revenue, growth rate and gross margin) of Acute Repetitive Seizures industry.
3. Global major countries (United States, Canada, Germany, France, UK, Italy, Russia, Spain, China, Japan, Korea, India, Australia, New Zealand, Southeast Asia, Middle East, Africa, Mexico, Brazil, C. America, Chile, Peru, Colombia) market size (sales, revenue and growth rate) of Acute Repetitive Seizures industry.
4. SWOT analysis, New Project Investment Feasibility Analysis, Upstream raw materials and manufacturing equipment & Industry chain analysis of Acute Repetitive Seizures industry.
5. Global market size (sales, revenue) forecast by regions and countries from 2019 to 2024 of Acute Repetitive Seizures industry.

Research Methodology: Global Acute Repetitive Seizures Market
  • Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please Request a Sample Report.
  • Demand Side Primary Contributors: OEMs, Industrial Professionals, Researches, Suppliers and Distributors, Group Purchasing Organizations, Associations, Insurers, Universities, Technological Writers, Scientists, Promoters, Investors among others.
  • Supply Side Primary Contributors: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, Regulatory Affairs Managers among other

Table of Contents 
Chapter 1 Methodology and Scope
  1.1 Research Methodology
  1.2 Research Scope and Assumptions
  1.3 List to Data SourcesChapter 2 Executive SummaryChapter 3 Market Variables, Trends & Scope
  3.1 Market Segmentation
  3.2 Acute Repetitive Seizures Market
  3.3 Market Driver Analysis
      3.3.1 Presence of strong pipeline and increasing initiatives for R&D
      3.3.2 Presence of treatment gap in adequate seizure control
      3.3.3 Other drivers
  3.4 Market restraint Analysis
      3.4.1 Cost of treatment
  3.5 Penetration Mapping
  3.6 Caregiver’s perception on route of
| 

Request a sample

Fill below form to request a sample


Please fill this form to enquire before buying


You can request for discount regarding the report by using below form